Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study by Baraket, Melissa et al.
RESEARCH Open Access
Is low dose inhaled corticosteroid therapy as
effective for inflammation and remodeling in
asthma? A randomized, parallel group study
Melissa Baraket
1,2,3,4*, Brian GG Oliver
1,2, Janette K Burgess
1,2, Sam Lim
5, Gregory G King
1,2,6,7 and Judith L Black
1,2
Abstract
Background: While most of the clinical benefits of inhaled corticosteroid (ICS) therapy may occur at low doses,
results of dose-ranging studies are inconsistent. Although symptom/lung function response to low and high dose
ICS medication is comparable, it is uncertain whether low dose ICSs are as effective as high dose in the treatment
of inflammation and remodeling.
Methods: 22 mild or moderate asthmatic adult subjects (corticosteroid free for > 2 months) participated in a
randomized, parallel group study to compare effects of fluticasone propionate (FP) 200 mcg/day and 1000 mcg/
day. Alveolar macrophage (AM)-derived cytokines and basement membrane thickness (BMT) were measured at
baseline and after 7 weeks treatment while symptoms, spirometry, exhaled nitric oxide (eNO) and airway
hyperresponsiveness (AHR) to mannitol at baseline and 6 weeks.
Results: FP improved spirometry, eNO, symptoms and AHR with no difference between low and high dose FP.
Both high and low dose FP reduced GM-CSF, TNF-alpha and IL-1ra, with no change in BMT and with no
differences between low and high dose FP.
Conclusions: 200 μg/day of FP was as effective as 1000 μg/day in improving asthma control, airway inflammation,
lung function and AHR in adults in the short term. Future studies should examine potential differential effects
between low and high dose combination therapy (ICS/long acting beta agonist) on inflammation and airway
remodeling over longer treatment periods.
Keywords: asthma, corticosteroids, airway hyperresponsiveness, alveolar macrophage, airway inflammation, airway
remodeling
Background
Corticosteroids are the most effective medication for the
prevention and treatment of asthmatic inflammation.
Many dose-ranging studies have been conducted to
examine the dose-response relationship of ICSs in the
treatment of asthma in adults and children [1-17]. The
adverse effects of inhaled corticosteroids (ICSs) have
been clearly shown to be dose-related in both adults and
children in numerous studies [18-25]. Although it has
been suggested that most of the clinical benefits of ICSs
occur at low doses [6,26], the results of dose-ranging stu-
dies are inconsistent. Some data show no dose-response
for FEV1 or asthma symptoms [8-11,13,27-29], for airway
hyperresponsiveness [7,14,15] or exhaled nitric oxide
[15], while other data show a significant dose-response
for clinical outcomes [2-5,7,9,12,16,17,30,31].
Evidence for equivalent effects on underlying airway
inflammation and remodeling of low dose and high dose
ICS therapy is lacking. In vitro, the degree of suppres-
sion of some inflammatory cytokines and the degree of
upregulation of anti-inflammatory cytokines is depen-
dent on the dose of corticosteroid [32,33]. However,
there are no in vivo randomized studies comparing the
effects of low and high dose ICS on production of clini-
cally relevant cytokines.
Alveolar macrophages (AMs) normally represent the
majority of cells isolated by bronchoalveolar lavage
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any medium, provided the original work is properly cited.(BAL) and express allergen-specific low affinity immu-
noglobulin E (IgE) receptors on their surface [34] which,
when activated, release pro-inflammatory mediators and
anti-inflammatory regulators including chemokines (IL-
8, MCP-1, MIP-1a), anti-inflammatory cytokines (IL-1ra
a n dI L - 1 0 )a n dp r o - i n f l a m matory cytokines (TNF-a,
GM-CSF, IL-6 and IL-1b) [35]. Endobronchial allergen
challenge significantly increases expression of activation
markers on AMs and correlates with AHR to methacho-
line [36]. The pro-inflammatory cytokine granulocyte
macrophage-colony stimulating factor (GM-CSF),
secreted by AMs, promotes myeloid cell differentiation,
stimulates antigen presenting cells, prolongs eosinophil
survival [37] and is elevated in BAL and bronchial biop-
sies in asthma and after allergen challenge [38-41]. Neu-
tralisation by GM-CSF antibodies in mice abolishes
ovalbumin-induced AHR and mucus cell hyperplasia
[42]. In vitro incubation of peripheral blood mononuc-
lear cell cultures with beclomethasone dipropionate
(BDP) or fluticasone propionate (FP) dose-dependently
inhibits allergen-induced GM-CSF in atopic asthmatics
[32]. Tumour necrosis factor-alpha (TNF-a)i sa n o t h e r
pro-inflammatory mediator secreted by AMs which is
increased in symptomatic asthmatics and enhanced by
allergen challenge. In vitro incubation with TNF-a
increases human airway smooth muscle responsiveness
[43]. Inhaled recombinant TNF-a increases AHR to
methacholine [44]. In vitro incubation of alveolar
macrophages with fluticasone or budesonide results in
dose-dependent inhibition of lipopolysaccharide (LPS)-
induced TNF-a protein secretion [33].
AMs secrete the anti-inflammatory cytokine interleukin-
10 (IL-10) which inhibits production of many pro-inflam-
matory cytokines [45], suppresses allergic inflammation by
inhibiting T helper 2 cell cytokines [46], shortens eosino-
phil survival and attenuates induction of IgE synthesis by
IL-4 [47]. Studies of the effects of corticosteroid treatment
on IL-10 are mixed. IL-10 expression is greater during
budesonide treatment compared with placebo [48] and
serum IL-10 increases after triamcinolone [49] while inhi-
bition of IL-10 by corticosteroid treatment can also occur
[50].
Another anti-inflammatory cytokine secreted by AMs is
interleukin-1 receptor antagonist (IL-1ra) which is an
endogenous means of protection against inflammatory
r e s p o n s e si nd i s e a s e ss u c ha sa s t h m aa n dr h e u m a t o i d
arthritis by inhibiting the pro-inflammatory mediator
interleukin-1beta (IL-1b). More macrophages express IL-
1b in asthma [51] and IL-1ra serum levels increase during
asthma exacerbations [52]. In animal studies, aerosol IL-
1ra prior to histamine challenge prevents bronchial hyper-
responsiveness [53]. Inhaled BDP in asthmatic subjects
inhibits epithelial expression of IL-1b without inhibition of
IL-1ra, favouring an anti-inflammatory shift in the ratio of
IL-1b/IL-1ra [54].
T h e r ei sa l s os o m ee v i d e n c ef o rd o s er e l a t e dd i f f e r -
ences in the effects of corticosteroids on bronchial
mucosal basement membrane thickness (BMT) [55,56]
but whether low dose ICS therapy, while sufficient to
control asthma symptoms, is also adequate to improve
airway remodeling is unknown.
The null hypothesis of this study is that low dose ICS
therapy is as efficacious as high dose therapy, for asthma
control, airway inflammation and remodeling in adults.
Our aim was to examine differences in response to high
and low dose ICS, in asthma control, airway inflamma-
tion, AHR and airway remodeling in mild to moderate
adult asthmatics who were previously corticosteroid free
for over two months.
Methods
Subjects
Adult volunteers were recruited, aged 19-30 years, with
intermittent or mild persistent or moderate persistent ato-
pic asthma (according to Global Initiative for Asthma,
Global Strategy for Asthma Management and Prevention,
NIH Publication, Updated 2005). Inclusion criteria were
asthma symptoms in the preceding 12 months and posi-
tive mannitol bronchial provocation test. Exclusion criteria
were baseline FEV1 less than 60% predicted, inhaled or
systemic corticosteroid treatment in the preceding
2 months, smoking in the preceding 12 months, greater
than 5 pack year smoking history and symptoms of upper
respiratory tract infection in the past 6 weeks. The study
was approved by the Ethics Review Committee of Royal
Prince Alfred Hospital in the Sydney South West Area
Health Service (protocol number X02-0137).
Study design
This was a double-blind, randomized, parallel group
comparison of short term low dose (100 μg twice daily)
versus high dose (500 μg twice daily) inhaled fluticasone
propionate (FP) via metered dose aerosol and large
volume spacer (GlaxoSmithKline). Bronchoscopy with
lavage and biopsies and bronchodilator reversibility
assessment were performed before and after 7 weeks
treatment. The other clinical measurements were
obtained before treatment and one week prior to the
second bronchoscopy, that is, after 6 weeks treatment.
The canisters were weighed before and after the treat-
ment period to confirm adherence. Patients were pro-
vided with salbutamol metered dose aerosol, 100 μg,
used as needed for asthma symptoms. Skin prick testing
was done with a panel of 12 common aeroallergens to
assess atopic status. A positive wheal was 3 mm or
more in the presence of a negative control.
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AHR was measured by bronchial provocation with dry
powder mannitol [57]. The test was terminated when
the fall in FEV1 reached at least 15% of baseline or after
a cumulative mannitol dose of 635 mg [58]. Response
dose ratio (RDR) [57] was the final percent fall in FEV1
divided by the corresponding cumulative dose of manni-
tol (%/mg). The provocative dose of mannitol causing a
15% or greater fall in FEV1 (PD15) was calculated by
linear interpolation. The mannitol doubling dose differ-
ence (DDD(RDR)) was calculated as [log(RDR) pre FP -
log(RDR) post FP]/log(2).
Exhaled nitric oxide (eNO)
Exhaled air was collected, prior to any lung function
tests, in a nitric oxide impermeable polyethylene reser-
voir bag using a slow vital capacity manoeuvre via a rota-
meter to ensure an expiratory flow rate of 200 mL/s. The
fraction of eNO (ppb) was measured offline using a che-
miluminescence analyzer (42C, Thermo Environmental
Instruments, MA, USA).
Bronchoscopy, alveolar macrophage (AM) culture and AM
stimulation, RNA extraction and bronchial biopsy
Three endobronchial biopsies before and after 7 weeks of
treatment were snap frozen in optimal cutting tempera-
ture medium and stored at -80°C for later sectioning. AMs
were isolated from bronchoalveolar lavage fluid by adhe-
sion. After rinsing and reapplication of culture medium,
AMs were incubated with or without lipopolysaccharide
(LPS) for 24 hours, after which supernatants were stored
at -80°C for cytokine protein assay and AMs were har-
vested for RNA extraction.
AM cytokine quantification
After reverse transcription, quantitative PCR for each
cytokine was performed (Assays-on-Demand, Applied
Biosystems, Foster City, California) to obtain a threshold
cycle (Ct) with normalisation to 18S. Cytokine protein
concentration in AM culture supernatants was quantified
by enzyme-linked immunosorbent assay (ELISA) (Duo-
Set, R&D Systems, Minneapolis, USA).
Basement membrane thickness (BMT)
Frozen biopsies were sectioned at -18°C at a thickness of
7 μm. Cryosections were stored at -80°C for later staining
with haematoxylin and eosin which were then photo-
graphed under light microscopy at 60× power. Transverse
measurements of the basement membrane, perpendicular
to the mucosal surface, were taken at 10-20 μm intervals
where the basement membrane appeared intact, clearly
delineated and uniform. The mean BMT was calculated
from seven to ten measurements on each of two to four
sections cut from each of two to three biopsies.
Statistical analysis
Statistical analyses were conducted using SPSS. Nonpara-
metric variables (eNO, serum IgE, PD15, and RDR) were
log transformed to normal distributions. Comparisons of
means for normally distributed data (FEV1, BMT) were
calculated by paired samples t-test for paired data and
independent samples t-test for unpaired data. For Juniper
Asthma Control Questionnaire scores [59], change in
threshold cycle (ΔCt) and ELISA values which were non-
normally distributed, medians were compared using the
Wilcoxon test for paired samples and the Mann-Whitney
U test for unrelated samples. Given the lack of available
data quantifying the dose-dependent effects of inhaled cor-
ticosteroids on airway cytokines, the sample size was
extrapolated from a study of the effects of inhaled budeso-
nide on alveolar macrophage GM-CSF, TNF-alpha and
IL-10 protein levels (pg/mL) [48] and a study of inhaled
flunisolide on TNF-a protein [60]. A sample size of 11 sub-
jects in each group was calculated to achieve a power of
80% and alpha of 0.05 to detect a difference of 1500 pg/
mL in GM-CSF and 260 pg/mL in IL-10 based on a stan-
dard deviation of 1250 pg/mL for GM-CSF and 220 pg/
mL for IL-10.
Results
Twenty three subjects completed the protocol in full.
Paired clinical and in vitro data were available for 22
participants, of whom 11 had been randomized to low
dose and 11 to high dose FP.
Baseline (pre FP) characteristics
Clinical baseline characteristics of the two treatment
groups were not statistically different (table 1). Fifteen had
reported symptoms and had used a rescue short-acting
b2-agonist in the preceding 4 weeks, 21 in the preceding 6
months and all in the preceding 2 years. Sixteen subjects
had taken ICSs previously (7 in low dose and 9 in high
dose FP group) at or longer than 2.5 months prior to
study entry, with a median interval since last corticosteroid
use of 9 months. Twenty-two had never smoked, while 1
had a 0.2 pack year history and ceased 2 years prior. All
subjects were atopic on allergen skin testing and had sig-
nificant AHR to mannitol.
Comparison of the change in each endpoint between low
and high dose FP
There were no significant differences in mean or median
changes in any clinical parameters between low and
high dose FP groups (table 2). No statistically significant
differences were found in median changes in AM cyto-
kine mRNA expression or protein production between
low and high dose FP groups. The difference in mean
changes in BMT between low and high dose FP was
also not statistically significant.
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parameters
Because no significant differences were found between
the low and high dose treatment groups, the effect of FP
on the 22 asthmatics as a single group was evaluated. As
s h o w ni nF i g u r e1 ,F Pr e s u l t e d in significant improve-
ment in FEV1 % predicted, eNO and Juniper symptom
score in this group of asthmatic subjects. There was also
marked attenuation of AHR manifest by a significant fall
in RDR after FP. Significant improvements were also
Table 1 Clinical baseline characteristics of the asthmatic subjects grouped into low and high dose FP treatment arms
Low Dose FP
(n = 11)
High Dose FP
(n = 11)
Mean (SD) Mean (SD) p value
Age (yrs) 21.7 (2.9) 22.3 (4.0) 0.72
Height (m) 1.7 (0.1) 1.8 (0.1) 0.24
Weight (kg) 74.1 (15.7) 86.8 (24.0) 0.16
Age of asthma onset (yrs) 6.7 (2.8) 4.8 (4.2) 0.22
Duration of asthma (yrs) 14.5 (4.0) 16.5 (6.1) 0.37
FEV1 (L) 3.49 (0.56) 3.63 (0.74) 0.63
FEV1 % predicted 85.6 (12.6) 84.5 (12.1) 0.84
FVC (L) 4.59 (0.87) 4.79 (0.86) 0.60
FEV1/FVC ratio (%) 77.4 (12.3) 75.9 (7.3) 0.74
Bronchodilator response (%) 5.6 (6.5) 7.0 (4.0) 0.54
Geometric Mean
(95% GR)
Geometric Mean
(95% GR)
p value
Exhaled nitric oxide (ppb) 22.5 (5.7-88.5)) 24.6 (5.7-106.6) 0.77
Total serum IgE (kU/L) 246.7 (19.4-3142.4) 411.7 (34.7-4884.3) 0.36
PD15 (mg) 178.0 (29.3-1080.2) 96.8 (20.1-465.8) 0.11
RDR (%/mg) 0.087 (0.015-0.478) 0.145 (0.030-0.668) 0.16
Median (IQR) Median (IQR) p value
Juniper ACQS 1.0 (0-2.0) *1.0 (0-2.0) 0.67
GR = geometric range, IQR = interquartile range, *n = 10
Table 2 Change in each endpoint after FP in low and high dose treatment arms
Low dose FP
(n = 11)
High dose FP
(n = 11)
Mean (SD) Mean (SD) p value
change in FEV1 (L) 0.291 (0.512) 0.364 (0.356) 0.703
change in percent predicted FEV1 (%) 6.5 (11.1) 8.0 (7.1) 0.719
change in FEV1/FVC ratio after FP (%) 3.5 (4.6) 5.7 (6.1) 0.336
change in Bronchodilator response (%) 0.1 (7.8) 2.7 (5.5) 0.376
change in log RDR (%/mg) 0.955 (0.530) 0.751 (0.433) 0.335
change in log exhaled NO (ppb) 0.307 (0.259) 0.427 (0.304) 0.331
Mannitol Doubling Dose Difference 3.2 (1.8) 2.5 (1.4) 0.335
change in basement membrane thickness (μm) -0.27 (1.08) 0.56 (1.38) 0.133
Median (IQR) Median (IQR) p value
change in Juniper ACQS 0.5 (0-1.0) 1.0 (0-1.0) 0.969
change in LPS induced TNF-alpha mRNA (Ct) 0.1 (-0.7-1.7) 0.7 (-0.4-2.1) 0.797
change in LPS induced GM-CSF mRNA (Ct) 1.7 (-1.4-3.8) 2.9 (-1.9-5.0) 0.748
change in LPS induced IL-1ra mRNA (Ct) 3.2 (2.0-4.3) 3.3 (1.3-5.7) 0.606
change in LPS induced IL-10 mRNA (Ct) -0.6 (-1.2-1.7) 0.5 (-0.7-1.2) 0.332
change in LPS induced TNF-alpha protein (pg/mL) 830 (-3888-1302) -2860 (-9173-2716) 0.395
change in LPS induced GM-CSF protein (pg/mL) 307 (-414-2986) 418 (-619-1154) 0.768
change in LPS induced IL-1ra protein (pg/mL) 4035 (1493-58151) 10166 (-1631-15164) 0.922
change in LPS induced IL-10 protein (pg/mL) 0.5 (-75.6-19.2) 1.3 (-44.5-79.7) 0.622
SD = standard deviation, IQR = interquartile range, Ct = threshold cycle
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3.89L (SD 0.70), p = 0.002] and FEV1/FVC ratio [pre FP:
77% (SD 9.9%), post FP: 81% (SD 7.4%), p = 0.001].
LPS significantly enhanced the quantity of cytokine
mRNA expressed and protein produced by AMs. FP
treatment significantly reduced constitutive mRNA
expression of GM-CSF, TNF-a and constitutive or LPS
induced IL-1ra mRNA (Figure 2) and protein (Figure 3).
There was no significant effect of inhaled FP on GM-
CSF or TNF-a protein concentrations. There was no
significant effect of inhaled FP on IL-10 which was in
many samples below the lower limit of detection.
There was no significant change in BMT in the group
as a whole (n = 22), 9.21 μm (SD 1.02) before and
9.06 μm (SD 0.91) after FP treatment.
Discussion
In this study we found that seven weeks of low dose ICS
treatment in adults with mild to moderate asthma, who
were corticosteroid free for over 2 months, is as effective
in controlling airway inflammation as high dose therapy,
measured by constitutive mRNA expression of GM-CSF,
TNF-a and constitutive or LPS induced IL-1ra mRNA
and protein in BAL. Low and high doses were also
equally effective in controlling asthma in terms of symp-
toms, spirometry, eNO and AHR after 6 weeks, which is
consistent with previous data [6,26]. We found no sig-
nificant effects on airway remodeling by either dose
after 7 weeks, as measured by change in basement
membrane thickness.
There have been previous ICS dose-ranging trials which
have not found differential clinical effects between dose
arms. Meta-analyses have revealed plateaus in the ICS
dose-response curve beginning at 100-200 μgo fF Pp e rd a y
with a peak benefit at 500 μg/day [11] or most of the clini-
cal efficacy attained with an FP dose of 200 μg/day [6] or
300-600 μg/day of budesonide (BUD) [26]. However, con-
trol of underlying inflammation and remodeling was not
assessed and individual patients with more severe asthma
may require higher doses to achieve the corresponding
maximal effects. Previously published evidence suggests
that AHR, which is loosely related to inflammation, may be
(a) (b)
(c) (d)  
Figure 1 Effects of FP on clinical parameters (n = 22). (a) FEV1 % predicted, (b) Exhaled nitric oxide (p value derived from log eNO means),
(c) Juniper ACQS, (d) log RDR for mannitol. Columns represent means and error bars represent 95% confidence intervals. Juniper scores are
depicted by box and whisker plots with medians and interquartile ranges (*n = 21 for post Juniper ACQS).
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or symptoms [9,12,31,61] and a dose-dependent rate of
reduction of eNO and asthma symptoms has been
observed [7,16,17]. In a meta-analysis of sixteen trials using
multiple drug formulations (FP, triamcinolone, BUD and
mometasone), a statistically significant inhaled corticoster-
oid dose-response relationship was found for morning PEF
and a dose-response relation for FEV1 was found for BUD
[2]. Asthma symptom score was also differentially affected
by the dose of FP or triamcinolone, in contrast to the pre-
sent study finding of no difference in change in Juniper
score between the two doses. This absence of difference in
the present study may be due to a milder degree of asthma
and smaller sample size.
D e s p i t et h es m a l ls a m p l es i z ei nas t u d yb yC h e t t ae t
al. [56] (8 in each group), there were significant differ-
ences in a number of in vitro inflammatory indices
between low and high dose inhaled steroid treatment.
High dose treatment resulted in a significant decrease in
basement membrane thickness, number of vessels, vas-
cular area and mean vessel size whereas no change was
observed with low dose. Like the current study findings,
there were no significant differences in the improve-
ments in AHR and asthma symptom scores between the
groups. The lack of difference between high and low
dose ICS effect on inflammatory markers in the present
study, compared with the findings of Chetta et al. [56]
could be due to milder asthma in our subjects since
none had previously taken long term ICS regularly. This
is supported by the correlation observed between base-
line severity and magnitude of improvement in
outcomes.
Modulation of alveolar macrophage inflammatory
r e s p o n s e si sa ni m p o r t a n tm e c h a n i s mu n d e r l y i n gI C S
efficacy in asthma [34-36,62-65]. There are no published
randomized studies examining the dose-response rela-
tionship of the effect of ICSs on pro- and anti-inflam-
matory cytokine production in asthma. In the present
(a) (b)
(c) (d)
Figure 2 Comparison of cytokine mRNA expression pre and post FP (n = 22). (a) TNF-a, (b) GM-CSF, (c) IL-1ra, (d) IL-10. Results are
normalized for 18S. Ct = threshold cycle. LPS = Lipopolysaccharide. Control = unstimulated sample. Graphical representation is by box and
whisker with medians and interquartile ranges. Note: an increase in threshold cycle indicates a decrease in quantity of mRNA present.
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of the pro-inflammatory cytokines GM-CSF and TNF-a.
The change in GM-CSF protein levels after FP treat-
ment was smaller than the estimated effect size of 1500
pg/mL. This estimate was derived from a study which
had assessed the effect of inhaled budesonide (800 μg
twice daily) in comparison to placebo [48], given the
lack of available data quantifying the dose-dependent
effects of inhaled corticosteroids on airway cytokines. A
smaller effect size would be expected between two active
treatment arms of different doses than between active
treatment and placebo but, while this difference may be
considered clinically significant, a greater number of
participants in each group would have been required to
show statistical significance. The effect size from two
previous studies which measured alveolar macrophage
TNF-a protein reduction post inhaled flunisolide [60]
(in the order of 50 pg/mL) differed greatly compared
with post inhaled beclomethasone [66] (in the order of
140,000 pg/mL). Therefore, although TNF-a is an
important biological endpoint in this study, the effect of
inhaled steroid treatment on TNF-a may depend on fac-
tors that are, as yet, undefined making the lack of signif-
icant effect of FP on TNF- a protein in the present
study difficult to interpret. Inhaled or systemic corticos-
teroids suppress inflammatory cytokines in vitro includ-
ing GM-CSF or TNF-a [40,48,66-73]. Previous in vitro
studies have shown that inhibition of pro-inflammatory
cytokines by corticosteroids is dose-dependent [32,33]
and it was postulated that the in vivo effects of treat-
ment on the same inflammatory markers would also be
dose-dependent. The present study, however, found no
significant difference between low and high dose inhaled
FP groups in the change in quantity of constitutive and
(a) (b)
(c)  
Figure 3 Comparison of cytokine protein concentrations pre and post FP (n = 22). (a) TNF-a, (b) GM-CSF, (c) IL-1ra. LPS =
Lipopolysaccharide. Control = unstimulated sample. Graphical representation is by box and whisker with medians and interquartile ranges.
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macrophages.
The anti-inflammatory cytokine IL-1ra mRNA expres-
sion and IL-1ra protein was also significantly suppressed
by inhaled FP in the present study. Previous studies
examining the effects of ICSs on IL-1ra show conflicting
results ranging from no effect [54,74] to elevation of IL-
1ra levels post treatment [52,74]. In the current study,
the finding of a reduction in IL-1ra mRNA and protein
after treatment with FP was unexpected considering this
cytokine has anti-inflammatory properties. Epithelial
expression of IL-1b is significantly inhibited by inhaled
BDP in asthmatic subjects without any significant con-
current inhibition of IL-1ra thus favouring an anti-
inflammatory shift in the ratio of IL-1b/IL-1ra [54]. It is
possible that the pro-inflammatory cytokine IL-1b,
which was not measured in this study, may have been
attenuated by FP to a greater extent than was IL-1ra,
thus resulting in a lower, more anti-inflammatory ratio
of IL-1b to IL-1ra levels.
The present study found no significant changes in the
anti-inflammatory cytokine IL-10 gene expression or
protein secretion resulting from treatment with FP. The
small differences in IL-10 protein levels detected after
FP treatment were substantially smaller than the 260
pg/mL reported previously. The levels of IL-10 were
close to the lower limit of detection in many subjects
making resolution of changes impossible. Previous stu-
dies have revealed mixed effects of corticosteroids on
IL-10, including no effect of in vitro dexamethasone
[75], elevation after high dose inhaled budesonide [48]
or inhaled triamcinolone [49] and inhibition in nonasth-
matics [50].
Basement membrane thickness in asthma is reduced
by corticosteroid treatment in some studies [73,76-80].
Although dose related differences in the effects of corti-
costeroids on bronchial mucosal BMT are apparent in
some studies [55,56], the current study did not demon-
strate a significant reduction in BMT after FP treatment
for 7 weeks. This is consistent with the findings of Bou-
let et al. for high dose FP [81]. Although two previous
studies have shown a significant effect of short term
treatment (six weeks) with medium or high dose inhaled
corticosteroid on BMT [56,76], longer treatment dura-
tion (three to twelve months) is more likely to alter
BMT [73,77,78,82-84].
Conclusions
An important feature of current asthma management
guidelines is the use of a maintenance dose of ICS which
is the minimum effective dose to achieve asthma symptom
control to limit the potential for adverse effects. Current
therapy guidelines also advocate alternative approaches to
achieve asthma control without increasing the ICS dose.
The addition of a long-acting beta agonist, leukotriene
antagonist and/or low dose theophylline represent exam-
ples of this approach. At least on a short term basis, our
results suggest that in stable mild or moderate adult asth-
matic patients, who are corticosteroid free for over 2
months, an FP equivalent dose of 200 μg/day may be just
as effective as 1000 μg/day in controlling cytokine driven
inflammation. Combining the different anti-asthmatic
mechanisms of other therapies with the attenuation of
cytokine driven inflammation by ICS might be a superior
and safer approach to achieving asthma control.
It is possible that differences in inflammation may
occur with longer term treatment and it would be
important to conduct longitudinal studies with larger
sample size to re-evaluate the dose-response relationship
of a wide repertoire of inflammatory mediators, along
with the probably smaller influence of dose on remodel-
ing and fibrotic markers. Additionally, prevention of
asthma exacerbations and decline in lung function
would be important endpoints to assess in a long term
study. It would also be useful to assess any differential
dose effects of combination inhaled corticosteroid/long
acting beta-agonist maintenance treatment, to firmly
establish whether such low dose therapy optimally sup-
presses underlying inflammation and prevents long term
airway remodeling and not just short term symptoms.
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